Gilead Sciences (GILD) Other Non-Current Assets (2009 - 2026)
Gilead Sciences' (GILD) quarterly Other Non-Current Assets came in at $4.8 billion in Q2 2026, up 17.86% on a YoY basis from $4.0 billion in Q2 2025, and up 4.33% quarter-over-quarter from $4.6 billion in Q1 2026.
Analysis
Gilead Sciences (GILD) Other Non-Current Assets (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has reported Other Non-Current Assets for 18 consecutive years, with $4.8 billion the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Other Non-Current Assets rose 17.86% year-over-year to $4.8 billion; the trailing twelve-month figure through Jun 2026 stood at $4.8 billion (up 17.86% YoY), and the FY2025 full-year result was $4.8 billion, up 28.55% from the prior year.
- Other Non-Current Assets improved to $4.8 billion in Q2 2026 per GILD's latest filing, from $4.6 billion in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $5.5 billion in Q3 2024 and bottomed at $3.8 billion in Q4 2024.
- Historically, Other Non-Current Assets has averaged $4.7 billion across 5 years, with a median of $4.8 billion in 2022.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets soared 30.81% in 2024, then retreated 25.39% in 2025.
- Over 5 years, Other Non-Current Assets stood at $4.8 billion in 2022, then fell by 0.17% to $4.8 billion in 2023, then fell by 21.35% to $3.8 billion in 2024, then increased by 28.55% to $4.8 billion in 2025, then dropped by 1.94% to $4.8 billion in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $4.8 billion, $4.6 billion, and $4.8 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 12.98 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 4.75 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 2.31 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 124.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 618.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 831.80 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 29.59 Mn |
| 10 | Insmed | 27.67 Bn | 26.51 Bn | 358.27 Mn | 104.44 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.75 Bn |
| Mar 31, 2026 | 4.55 Bn |
| Dec 31, 2025 | 4.85 Bn |
| Sep 30, 2025 | 4.87 Bn |
| Jun 30, 2025 | 4.03 Bn |
| Mar 31, 2025 | 3.87 Bn |
| Dec 31, 2024 | 3.77 Bn |
| Sep 30, 2024 | 5.49 Bn |
| Jun 30, 2024 | 4.77 Bn |
| Mar 31, 2024 | 5.19 Bn |
| Dec 31, 2023 | 4.79 Bn |
| Sep 30, 2023 | 4.20 Bn |
| Jun 30, 2023 | 5.11 Bn |
| Mar 31, 2023 | 4.95 Bn |
| Dec 31, 2022 | 4.80 Bn |
| Sep 30, 2022 | 4.62 Bn |
| Jun 30, 2022 | 4.86 Bn |
| Mar 31, 2022 | 5.13 Bn |
| Dec 31, 2021 | 4.96 Bn |
| Sep 30, 2021 | 4.74 Bn |